Structural Heart Abnormality
8
4
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (8)
Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease
Stereotactic Ablative Radiotherapy for the Treatment of Refractory Ventricular Tachycardia
Prince of Wales Hospital Structural Heart Registry
Autonomous Robotics for Transcatheter Cardiac Procedures
Harnessing ECG Artificial Intelligence for Rapid Treatment and Accurate Identification of Structural Heart Disease
Diagnosis of Structural Heart Disease Using MCG
REgiStry-based Cardiovascular qUality improvEment Research
The SALMANTICOR Study